Assembly Biosciences Stock Today

ASMB Stock  USD 15.37  0.57  3.85%   

Performance

2 of 100

 
Weak
 
Strong
Weak

Odds Of Distress

Less than 9

 
High
 
Low
Low
Assembly Biosciences is trading at 15.37 as of the 15th of July 2024, a 3.85 percent increase since the beginning of the trading day. The stock's open price was 14.8. Assembly Biosciences has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Note, on February 10, 2021, Representative Chris Jacobs of US Congress acquired under $15k worth of Assembly Biosciences's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
17th of December 2010
Category
Healthcare
Classification
Health Care
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus infection in the United States. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. The company has 6.35 M outstanding shares of which 18.86 K shares are presently shorted by private and institutional investors with about 1.07 trading days to cover. More on Assembly Biosciences

Moving against Assembly Stock

  0.38FENC Fennec PharmaceuticalsPairCorr
  0.33VRNA Verona Pharma PLC TrendingPairCorr
  0.32GOSS Gossamer BioPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Assembly Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President CEOJason Okazaki
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.06930.0469
Way Up
Pretty Stable
Total Current Liabilities41.2 M39.2 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total62.5 M57.1 M
Significantly Up
Slightly volatile
Total Assets130.2 M137.5 M
Notably Down
Slightly volatile
Total Current Assets102.4 M133.8 M
Way Down
Slightly volatile
Debt Levels
Assembly Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Assembly Biosciences' financial leverage. It provides some insight into what part of Assembly Biosciences' total assets is financed by creditors.
Liquidity
Assembly Biosciences currently holds 2.34 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Assembly Biosciences has a current ratio of 8.14, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Assembly Biosciences' use of debt, we should always consider it together with its cash and equity.

Change In Cash

(30.95 Million)
Assembly Biosciences (ASMB) is traded on NASDAQ Exchange in USA. It is located in 331 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 and employs 65 people. Assembly Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 89.95 M. Assembly Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 6.35 M outstanding shares of which 18.86 K shares are presently shorted by private and institutional investors with about 1.07 trading days to cover. Assembly Biosciences currently holds about 116.69 M in cash with 22.74 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.41.
Check Assembly Biosciences Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Assembly Biosciences is $89.95 Million. Assembly Biosciences retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that on February 10, 2021, Representative Chris Jacobs of US Congress acquired under $15k worth of Assembly Biosciences's common stock.
Check Assembly Ownership Details

Assembly Stock Institutional Holders

InstituionRecorded OnShares
Marquette Asset Management Inc.2024-03-31
K
Amundi2024-03-31
7.9 K
Acadian Asset Management Llc2024-03-31
5.9 K
Ubs Group Ag2024-03-31
3.2 K
Barclays Plc2024-03-31
K
Morgan Stanley - Brokerage Accounts2024-03-31
2.5 K
Tower Research Capital Llc2024-03-31
857
Rhumbline Advisers2024-03-31
199
Royal Bank Of Canada2024-03-31
79.0
Vanguard Group Inc2024-03-31
196.4 K
Millennium Management Llc2024-03-31
124.9 K
View Assembly Biosciences Diagnostics

Assembly Biosciences Historical Income Statement

At present, Assembly Biosciences' Income Tax Expense is projected to decrease significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 3.6 M, whereas Depreciation And Amortization is forecasted to decline to about 427.5 K. View More Fundamentals

Assembly Stock Against Markets

Assembly Biosciences Corporate Management

Nicole WhiteChief OfficerProfile
AO FRACPCEO DirectorProfile
Adam ZlotnickChief CoFounderProfile
Uri MDCoFounder AdvisorProfile
Michele AndersonChief OfficerProfile
Dr IVChief OfficerProfile

Already Invested in Assembly Biosciences?

The danger of trading Assembly Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Assembly Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Assembly Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Assembly Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Information and Resources on Investing in Assembly Stock

When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Assembly Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(10.58)
Revenue Per Share
2.65
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.34)
Return On Equity
(1.00)
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.